A Prospective, Non-randomized, Multicenter, Phase II Study of Nab-paclitaxel Combined With Bevacizumab for Unresectable Recurrent or Metastatic Neuroendocrine Carcinoma
Latest Information Update: 10 Jan 2024
At a glance
- Drugs Bevacizumab (Primary) ; Paclitaxel (Primary)
- Indications Neuroendocrine carcinoma
- Focus Therapeutic Use
- 14 Jan 2021 New trial record